Serdal KORKMAZ, Selahattin ERDEM, Ebru AKAY, Erdem Arzu TAŞDEMİR, Hatice KARAMAN, Muzaffer KEKLİK

Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?

Öz Background/aim: PD-1 (programmed death-1) is an immune checkpoint receptor that modulates T-cell activity in peripheral tissues via interaction with its ligands, PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2). Tumor cells upregulate PD-L1 or PD-L2 to inhibit this T lymphocyte attack. Our goal was to determine the PD-1 and PD-L2 expression rates of various hematologic malignancies, and evaluate whether PD-1 and PD-L2 expressions have an impact on prognosis. Materials and methods: For this purpose, pretreatment bone marrow biopsy specimens of 83 patients [42 multiple myeloma (MM), 21 acute leukemia, and 20 chronic lymphocytic leukemia (CLL)] were stained with monoclonal antibody immunostains of PD-1 and PD-L2. Results: As a result, the overall expression rate of PD-1 was 26.2%, 4.8%, and 60% in patients with MM, acute leukemia, and CLL, respectively, whereas the PD-L2 expression rate was 61.9%, 14.3%, and 10% in patients with MM, acute leukemia, and CLL, respectively. Conclusion: Finally, we concluded that the role of the PD-1 pathway can be demonstrated by immunohistochemistry (IHC). Since we evaluated whether there is a correlation between the (IHC) results and survival of patients with MM, acute leukemia, and CLL, we could not demonstrate meaningful evidence that these markers have an impact on prognosis.

Anahtar Kelimeler:

PD-1, PD-L2, multiple myeloma, acute leukemia, chronic lymphocytic leukemia

Tam Metin

Kaynak Göster

Bibtex	`@ { tbtkmedical577812, journal = {Turkish Journal of Medical Sciences}, issn = {1300-0144}, eissn = {1303-6165}, address = {}, publisher = {TÜBİTAK}, year = {2019}, volume = {49}, pages = {265 - 271}, doi = {}, title = {Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?}, key = {cite}, author = {Korkmaz, Serdal and Erdem, Selahattin and Akay, Ebru and Taşdemir, Erdem Arzu and Karaman, Hatice and Keklik, Muzaffer} }`
APA	Korkmaz, S , Erdem, S , Akay, E , Taşdemir, E , Karaman, H , Keklik, M . (2019). Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies? . Turkish Journal of Medical Sciences , 49 (1) , 265-271 . Retrieved from https://dergipark.org.tr/tr/pub/tbtkmedical/issue/45750/577812
MLA	Korkmaz, S , Erdem, S , Akay, E , Taşdemir, E , Karaman, H , Keklik, M . "Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?" . Turkish Journal of Medical Sciences 49 (2019 ): 265-271 <https://dergipark.org.tr/tr/pub/tbtkmedical/issue/45750/577812>
Chicago	Korkmaz, S , Erdem, S , Akay, E , Taşdemir, E , Karaman, H , Keklik, M . "Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?". Turkish Journal of Medical Sciences 49 (2019 ): 265-271
RIS	TY - JOUR T1 - Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies? AU - Serdal Korkmaz , Selahattin Erdem , Ebru Akay , Erdem Arzu Taşdemir , Hatice Karaman , Muzaffer Keklik Y1 - 2019 PY - 2019 N1 - DO - T2 - Turkish Journal of Medical Sciences JF - Journal JO - JOR SP - 265 EP - 271 VL - 49 IS - 1 SN - 1300-0144-1303-6165 M3 - UR - Y2 - 2021 ER -
EndNote	%0 Turkish Journal of Medical Sciences Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies? %A Serdal Korkmaz , Selahattin Erdem , Ebru Akay , Erdem Arzu Taşdemir , Hatice Karaman , Muzaffer Keklik %T Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies? %D 2019 %J Turkish Journal of Medical Sciences %P 1300-0144-1303-6165 %V 49 %N 1 %R %U
ISNAD	Korkmaz, Serdal , Erdem, Selahattin , Akay, Ebru , Taşdemir, Erdem Arzu , Karaman, Hatice , Keklik, Muzaffer . "Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?". Turkish Journal of Medical Sciences 49 / 1 (Şubat 2019): 265-271 .
AMA	Korkmaz S , Erdem S , Akay E , Taşdemir E , Karaman H , Keklik M . Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?. Turkish Journal of Medical Sciences. 2019; 49(1): 265-271.
Vancouver	Korkmaz S , Erdem S , Akay E , Taşdemir E , Karaman H , Keklik M . Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?. Turkish Journal of Medical Sciences. 2019; 49(1): 265-271.
IEEE	S. Korkmaz , S. Erdem , E. Akay , E. Taşdemir , H. Karaman ve M. Keklik , "Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?", Turkish Journal of Medical Sciences, c. 49, sayı. 1, ss. 265-271, Şub. 2019